RxDoctor Payments DataLook up a doctor →

Rola Gharib, MD

Dermatology · Morgantown, WVNPI 1760686927

Payments from drug & device makers

$1,348,642in general payments, 2019–2025

Across 1,619 payments — averaging $833.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$549K
  • AbbVie$148K
  • Eli Lilly$129K
  • Bristol Myers Squibb$121K
  • Pfizer$94K
  • Galderma Laboratories, L.p.$81K
  • plus $226K from 43 others
$2,488in research payments, 2019–2025

Across 1 payment — averaging $2488.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$2K

What the payments were for

  • Consulting fees$33,3448%
  • Speaking & faculty fees$302,20977%
  • Travel & lodging$29,3607%
  • Food & beverage$27,4127%
  • Education$6220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,348,642 in reported general payments places this provider in the 95th percentile of 39 dermatology providers in West Virginia.

See all dermatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$130,067
Medicare patients
473
Services billed
1,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab24$94,080
Taltz AutoinjectorIxekizumab12$81,657
OtezlaApremilast12$60,311
Doxycycline Ir-DrDoxycycline Monohydrate11$6,321
Tacrolimus14$3,279
Clobetasol Propionate59$1,805
Ketoconazole68$1,174
Clindamycin Phosphate24$1,053
Triamcinolone Acetonide67$1,047
Doxycycline Hyclate32$832
ValacyclovirValacyclovir Hcl16$344
Minoxidil23$84
Finasteride20$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$549,305$60,31112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 39 dermatology providers in West Virginia.

Other dermatology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →